With reference to Chapter 4, Section 9 of the Swedish
Financial Instruments Trading Act (SFS 1991:980), it is
hereby announced that the new issue of Series B stock units
during March 2012 has led to the below changes in the
number of stock units and votes in Artimplant AB.
Before the new issue: Series A stock units 575,000, Series
B stock units 117.914.580, total number of stock units
118.489.580 and the number of votes 123.664.580.
Increase due to new issue: Series B stock units
395.492.676.
After the new issue: Series A stock units 575.000, Series B
stock units 513.407.256, total number of stock units
513.982.256 and total number of votes 519.157.256.
Â
For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 31Â 746 56 00, +46Â 703 11 90
25
Further information at www.artimplant.com where one also
can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html
Â
Artimplant
Artimplant is a biomaterials company focused on solutions
to problems in orthopedic. We restore health through the
development, production and marketing of degradable
implants that regenerate body functions and improve quality
of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of
therapy areas. Artimplant produces implants for treatment
of osteoarthritis in hands and feet, for shoulder and other
soft tissue injuries.
Artimplant is a public company listed on the OMX Nordic
Exchange Stockholm in the Small Cap segment and in the
healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as
defined in the U.S. Private Securities Litigation Reform
Act of 1995. Readers are cautioned not to place undue
reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and
uncertainties impacting the Company's business
including increased competition; the ability of the Company
to expand its operations and to attract and retain
qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from
time to time in the Company's filings.
This is information which Artimplant shall make public
pursuant to the Swedish Financial Instruments Act and the
Swedish Securities Exchange and Clearing Operations Act
and/or stock market agreements. Information was made
available for publication on March 30, 2012 at 4 PM
(Swedish time).
The following files are available for download:
distributed by | This press release was issued by Artimplant AB and was initially posted at http://www.artimplant.com/investors-media/press-releases.html?releaseid=654764 . It was distributed, unedited and unaltered, by noodls on 2012-03-30 17:11:21 PM. The issuer is solely responsible for the accuracy of the information contained therein. |